Capital Research Global Investors, a registered investment adviser, initiated a new position in AbbVie Inc. (NYSE:ABBV) during Q4 2025, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor purchased 25,408,200 shares of the Healthcare company, valued at approximately $5.8B as of the filing date.
AbbVie Inc.'s stock currently trades at $221.88 with a market capitalization of $395.7B.